Spots Global Cancer Trial Database for A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity
Official Title: A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity
Study ID: NCT01586117
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the effect of intrarectal Amifostine administration on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.
Detailed Description: To evaluate the different use way of intrarectal Amifostine administration on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Radiation Oncology Depratment, Cancer Hospital, CAMS, Beijing, Beijing, China
Contact Details
Name: Jing Jin, M.D
Affiliation: Chinese Acedemy of Medical Scinences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
